至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth

Biomark Res. 2020-06-01; 
Le Qin, Ruocong Zhao, Dongmei Chen, Xinru Wei, Qiting Wu, Youguo Long, Zhiwu Jiang, Yangqiu Li, Haipeng Wu, Xuchao Zhang, Yilong Wu, Shuzhong Cui, Wei Wei, Huihui Yao, Zixia Liu, Su Cao, Yao Yao, Zhenfeng Zhang, Peng Li
Products/Services Used Details Operation
Custom Vector Construction … uPD-L1 contained the full-length gene of PD-L1 (GenBank NP_001254635.1, aa 1-176) and labeled with a truncated CD19. DNA sequences were synthesized by Genscript (Nanjing) Co., Ltd. (Nanjing, China) and cloned into the second-generation lentiviral vector pWPXLd … Get A Quote

摘要

unassigned: Chimeric antigen receptor T cells (CAR-T cells) therapy has been well recognized for treating B cell-derived malignancy. However, the efficacy of CAR-T cells against solid tumors remains dissatisfactory, partially due to the heterogeneity of solid tumors and T cell exhaustion in tumor microenvironment. PD-L1 is up-regulated in multiple solid tumors, resulting in T cell exhaustion upon binding to its receptor PD-1. unassigned: Here, we designed a dominant-negative form of PD-1, dPD1z, a vector containing the extracellular and transmembrane regions of human PD-1, and a CAR vector against PD-L1, CARPD-L1z, a vector employs a high-affinity single-chain variable fragment (scFv) against human PD-L1. These... More

关键词

CAR-T cells, Mesothelin, PD-L1, PDX